Company news
Crescita Therapeutics, Inc. (TSX:CTX) news
Crescita Therapeutics, Inc. news releases on 6ix. Latest, Jun 3, 2026: Crescita Therapeutics Inc. Announces Closing of Arrangement
Press releases & updates
Crescita Therapeutics Inc. Announces Closing of Arrangement
June 3, 2026
Crescita Therapeutics Inc. Announces Final Consideration Payable to Shareholders Pursuant to Arrangement with ClinActiv
June 1, 2026
Crescita Therapeutics Inc. Obtains Final Order Approving Plan of Arrangement
May 20, 2026
Crescita Obtains Shareholder Approval To Be Acquired By ClinActiv Holdings
May 14, 2026
Crescita Reports First Quarter 2026 Results
May 11, 2026
Crescita Announces Filing and Mailing of Special Meeting Materials and Receipt of Interim Order in respect of Arrangement with ClinActiv Holdings
April 22, 2026
Crescita Reports Q4 and Fiscal 2025 Results
March 31, 2026
Crescita Announces Definitive Agreement to Be Acquired by ClinActiv Holdings in an All-Cash Transaction at a Significant Premium
March 16, 2026
Crescita Reports Third Quarter 2025 Results
November 5, 2025
Crescita Reports Second Quarter 2025 Results
August 6, 2025
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
June 5, 2025
Crescita Therapeutics Announces Mutual Termination of Licensing Agreement with Croma Pharma GmbH for Pliaglis®
May 23, 2025
Crescita Therapeutics Announces Mutual Termination of Licensing Agreement with Croma Pharma GmbH for Pliaglis®
May 23, 2025
Crescita Reports First Quarter 2025 Results
May 14, 2025
Crescita Reports Q4 and Fiscal 2024 Results
March 18, 2025
Crescita Reports Third Quarter 2024 Results
November 6, 2024
Croma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe
June 1, 2023
Crescita Announces Filing of New Medical Device License
January 21, 2021
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid
November 26, 2020
Crescita Reports Third Quarter 2020 Results
November 12, 2020
Crescita Announces Licensing Agreement for Pliaglis® in China
November 5, 2020
Crescita Reports Second Quarter 2020 Results
August 12, 2020
Crescita to Receive One-time Cash Payment Following Amendment to Pliaglis® U.S. Licensing Agreement
July 28, 2020
Crescita Reports First Quarter 2020 Results
May 27, 2020
Crescita Therapeutics Announces the Results of its Annual General Meeting of Shareholders
May 14, 2020
Crescita Therapeutics Announces Extension of First Quarter 2020 Filings Due to COVID-19
April 28, 2020
Crescita Therapeutics Announces Measures in Response to COVID-19 Virus
March 24, 2020
Crescita Reports Q4 and Fiscal 2019 Results
March 18, 2020
Pliaglis® finally available in Canada
March 10, 2020
Crescita Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Studies for its Lead Pipeline Product in Patients with Plaque Psoriasis
February 11, 2020
Crescita Awarded Cannabis Research License from Health Canada
January 24, 2020
Crescita Secures Line of Credit with the Royal Bank of Canada Following Repayment in Full of Knight Therapeutics Loan
January 22, 2020
Crescita Signs Exclusive Distribution Agreement with FILLMED
January 20, 2020
Crescita Reports 2019 Third Quarter Results
November 7, 2019
U.S. Food and Drug Administration Approves Enhanced Formulation of Pliaglis®
November 5, 2019
Sundial and Crescita Sign Exclusive Partnership to Develop Cannabis and Hemp Topicals
October 28, 2019
Crescita Therapeutics Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City
September 5, 2019
Crescita Reports Profitable 2019 Second Quarter Results
August 8, 2019
United States Patent and Trademark Office Issues U.S. Patent Covering an Enhanced Formulation of Pliaglis®
July 16, 2019
Crescita Therapeutics to Host Investor Webcast on July 24, 2019
July 11, 2019
Crescita Therapeutics Inc. Receives 2nd Instalment of Up-Front Payment of Euro1.25 Million Following First Commercial Sale of Pliaglis by Cantabria in Italy
July 4, 2019
Crescita Therapeutics Inc. Announces Intention to Make Normal Course Issuer Bid
June 16, 2019
Crescita to Present at the 9th Annual LD Micro Invitational in Los Angeles, California
May 30, 2019
Crescita Therapeutics Engages Bristol Capital to Provide Investor Relations and Communications Services
May 29, 2019
Crescita Therapeutics Reports 2019 First Quarter Results
May 15, 2019
Crescita Therapeutics Strengthens Leadership Team with New Vice-President in Aesthetic and Cosmeceutical Business Unit
May 7, 2019
Crescita Therapeutics Signs Pliaglis® Out-Licensing Agreement with Cantabria Labs for Euro2.5M Upfront After Reacquiring Rest-of-World Rights
April 25, 2019
Crescita Therapeutics to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference in Toronto
April 17, 2019
Crescita Therapeutics Reports Fourth Quarter and Fiscal 2018 Results Record Annual Revenue of $16.6M and Adjusted EBITDA of $1.5M Strong Royalties and Sales Milestones
March 21, 2019
Crescita Therapeutics Inc.(TM) and Tetra Natural Health Collaborate to Enhance Transdermal Delivery of Beta-Caryophyllene in Tetra's Dermatology Product Portfolio
February 4, 2019